Next Article in Journal
From Herd Health to Public Health: Digital Tools for Combating Antibiotic Resistance in Dairy Farms
Next Article in Special Issue
Mitomycin C as an Anti-Persister Strategy against Klebsiella pneumoniae: Toxicity and Synergy Studies
Previous Article in Journal
Differences in the Dwell Time of Peripherally Inserted Central Catheters between Patients with Catheter Colonization and Those Developing Central Line-Associated Bloodstream Infection: A Single Centre Retrospective Cohort Study
Previous Article in Special Issue
Antifungal Biofilm Inhibitory Effects of Combinations of Diclofenac and Essential Oils
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 7
10.3390/antibiotics13070633
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran: Candida Species Distribution and Antifungal Susceptibility Patterns

by
Zeinab Soleimani Shiyadeh
1,
Shirin Farahyar
1,2,
Laleh Vahedi Larijani
3,
Justin Beardsley
4,5,
Noura Nouri
6,
Shahram Mahmoudi
1,
Shahla Roudbar Mohammadi
6,
Célia Fortuna Rodrigues
7,8,9,10,* and
Maryam Roudbary
1,4,5,*
1
Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran
2
Microbial Biotechnology Research Center (MBiRC), School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran
3
Department of Pathology, School of Medicine, Mazandaran University of Medical Sciences, Sari 48175-866, Iran
4
Sydney Infectious Diseases Institute, University of Sydney, Sydney, NSW 2145, Australia
5
Westmead Hospital, NSW Health, Sydney, NSW 2145, Australia
6
Department of Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115111, Iran
7
Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal
8
UCIBIO—Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal
9
LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal
10
ALiCE—Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal
*
Authors to whom correspondence should be addressed.
Antibiotics 2024, 13(7), 633; https://doi.org/10.3390/antibiotics13070633
Submission received: 3 May 2024 / Revised: 29 June 2024 / Accepted: 4 July 2024 / Published: 8 July 2024
(This article belongs to the Special Issue Drug Repositioning in Antimicrobial Therapy, 2nd Edition)
Versions Notes

Abstract

:
Candida species, typically part of the human skin and mucous membrane flora, can cause opportunistic fungal infections, notably urinary tract infections (UTIs), which are on the rise among hospitalized COVID-19 patients. The lack of understanding of UTIs in this population, coupled with the emergence of multidrug-resistant strains, poses significant challenges for effective treatment and further investigations. In this study, urine samples were collected from 70 COVID-19 patients with UTIs in sterile containers for microbiology examination. After microscopic observation, the isolates were identified both by phenotypic and molecular techniques such as multiplex PCR. Antifungal susceptibility testing (AFST) against fluconazole (Flu), itraconazole (Itr), and amphotericin B (AMB) was performed according to CLSI M27/S4 standard methods, with the frequency of isolates including Candida albicans (n = 20, 51.3%), Candida tropicalis (n = 15, 38.4%), Nakaseomyces glabrata (previously Candida glabrata) (n = 2, 5.1%), Pichia kudriavzevii (previously Candida krusei), and Candida parapsilosis (n = 1, 2.5%). All isolates of C. albicans, C. tropicalis, C. glabrata, and C. parapsilosis were sensitive to amphotericin B, while C. kruzei was resistant to AMB. Around 70% of C. albicans isolates were sensitive to Flu; 20% of C. tropicalis were resistant to itraconazole, while 33% were resistant to fluconazole. C. albicans and C. tropicalis were the main causes of candiduria in infected cases and both Flu and AMB showed good results in AFST in these species. Performing drug susceptibility testing for clinical isolates of Candida spp. provided guidance for appropriate management and control, and timely antifungal treatment.

1. Introduction

Candida species can colonize skin and mucosal surfaces and, given the right conditions, can cause opportunistic infections—the most worrying of these are blood stream infections but many other body sites can be affected, including the genitourinary system [1]. Coronavirus disease 2019 (COVID-19) has become a global issue because of its high prevalence leading to hundreds of millions of deaths and affecting healthcare systems worldwide. It has been clearly demonstrated that the incidence of opportunistic fungal infections increased in relation to the COVID-19 pandemic. Overall, rates in hospitalized patients especially ICU-admitted cases (9.6%) were significantly greater during the COVID-19 pandemic than prior [2,3,4].
A wide range of bacteria, viruses, and fungi can cause UTI. Although the majority are caused by bacteria, around 10–15% are caused by Candida species [5]. Candiduria—the presence of Candida species in urine—is common in at-risk inpatients such as those with diabetes mellitus, long-term use of antibiotics and corticosteroids, hospitalized people with a urinary catheter, as well as critically ill patients like those with COVID-19 [6]. COVID-19 patients can experience immunosuppression, particularly due to the use of steroids, attributing it to dysregulated immune responses. This creates a favourable environment for the development of persistent fungal co-infections. Additionally, the collateral effects of host recognition pathways, crucial for activating antiviral immunity, induce a highly permissive inflammatory environment, promote fungal pathogenesis, and increase the susceptibility of COVID-19 patients to opportunistic fungal infections [2]. Candiduria is defined as 104–105 CFU/mL of yeasts detected from urine, whereas a Candida UTI is mainly characterized by 105< CFU/mL being detected, which varies from asymptomatic to some clinical presentation of UTI include dysuria, frequent and suprapubic pain as well as puria to invasive candidiasis [7,8]. Although therapy is not necessitated in colonized patients [9], effective and timely treatment is recommended in cases with predisposing factors and patients with clinical signs of infection [10]. Candiduria can signal systemic candidiasis, including candidemia, though this is rare from UTIs alone. In immunocompromised individuals or those with underlying medical conditions, Candida in urine may lead to bloodstream infection. Thus, systemic candidiasis should be considered with candiduria, particularly in high-risk patients. It has been reported that in critically ill patients or those undergoing surgical procedures, candidemia rates from UTI sources may reach up to 10% [11].
The diversity of Candida species in candiduria patients has been reported from various studies. Although C. albicans is still the predominant agent in UTI, non-albicans Candida (NAC) such as C. glabrata, C. krusei, C.parapsilosis, C. tropicalis, Candida kefyr, Candida dubliniensis, or Candida guilliermondii (Meyerozyma guilliermondii), has increased over the world in clinical settings [12]. Recently, Candida auris was also isolated from a candidemia patient secondary to chronic UTI [13]. Unfortunately, several of these species have intrinsically reduced the susceptibility to antifungal drugs or the propensity to acquire resistance. This has led to a high rate of morbidity and mortality and growing concerns as it poses a significant threat to public health [14,15]. In fact, species of the genera Candida are among the most important yeasts in terms of pathogenicity, which have the ability to form biofilms (adherent microbial community) on multiple medical surfaces. These biofilms can form in urinary catheters, which lead to persistent Candida infections and higher rates of therapeutic failure [16,17]. Although some studies have addressed the most common fungal infections in COVID-19 cases in Iran [18] and other countries, including aspergillosis [19,20], mucormycosis [21,22], and candidiasis [23,24] in COVID-19 patients, candiduria’s impact on COVID-19 patients is poorly understood and data regarding Candida UTI are insufficient. Additionally, the epidemiology of Candida UTIs varies profoundly by region [25,26], and, as a consequence, the assessment of local data is vital to elucidate trends over time. Moreover, understanding the causative agents and antifungal susceptibility pattern of Candida spp. in COVID-19 patients with candiduria is essential for the control, optimal management, and effective treatment of disease. To address this gap, in this study, we investigated the distribution of Candida species isolated from hospitalized COVID-19 patients suffering from UTI in Iran with determined antifungal susceptibility testing, to gain an insight into the therapeutic options to increase the patient outcome, using appropriate antifungal treatment.

2. Results

2.1. Distribution of Candida spp. and Patient Features

In this study, 39 Candida species were recovered from 70 urine sample using both morphological and molecular methods. Direct examination of urine specimens indicated yeast budding cells in candiduria positive cases. C. albicans was the predominant isolate from UTI (n = 20, 51.3%), followed by C. tropicalis (n = 15, 38.4%), C. glabrata (n = 2, 5.1%), C. krusei, and C. parapsilosis (n = 1, 2.5%). The multiplex PCR result confirmed CHROMagar Candida identification. Patients’ characteristics are summarized in Table 1. In this study, most UTI cases were female (29, 74.35%) with fewer men (10, 25.64%). The highest rate of infection was detected among individuals aged over 60 years (51.21%), followed by those in the 30–60 age range. Diabetes type 2 was the most frequent predisposing factor in patients with UTI (46.51%). Other underlying diseases contributed to UTI detected in patients who used antibiotics and immunosuppressive drugs, and to their duration of hospital stay. None of the patients included in our study had received antifungal therapy prior to the diagnosis of UTI. The majority of patients had chronic kidney disease, or chronic obstructive pulmonary disease (COPD), were more susceptible to severe COVID-19 infections, and necessitated the use of immunosuppressive drugs for management. The length of immunosuppressive therapy depended on the patient response; generally, in our study, patients received immunosuppressive drugs for 10–14 days during hospitalization. This timeframe was based on clinical assessment and the patient’s response to therapy.

2.2. Antifungal Susceptibility Testing (AFST)

AFST against FLZ, ITZ, and AMB was performed according to the CLSI protocol for Candida spp. The result of AFST indicated that AMB (0.25 μg/mL) effectively inhibited 100% growth in all tested Candida species. ITZ (0.5 μg/mL) and FLZ (2 μg/mL) exhibited a 50% reduction in growth inhibition of Candida species isolated from patients. All isolates of C. albicans, C. tropicalis, C. glabrata, and C. parapsilosis were sensitive to AMB, except C. kruzei, which demonstrated resistance. Notably, 70% of C. albicans isolates were sensitive to FLZ and only one was detected as resistant. A total of 20% of C. tropicalis were resistant to ITZ and 33% were resistant to FLZ. Additionally, two isolates of C. glabrata were resistant to both FLZ and ITZ. One isolate of C. krusei was resistant to all antifungal drugs, FLZ, ITZ, and AMB, whereas C. parapsilosis was dose-dependently sensitive to FLU and sensitive to ITZ. AFST findings against all isolates are shown in Table 2.

3. Discussion

COVID-19 patients are known to be at high-risk of disseminated fungal infections, with high mortality and morbidity [27]. Nonetheless, UTIs have not been well-studied in this population. Till now, only limited data are available regarding Candida UTI in the COVID-19 population [28,29]. Understanding the causative agents responsible for candiduria in hospitalized COVID-19 patients, as well as the antifungal susceptibility patterns of Candida spp. isolates, provides valuable insights for early diagnosis, treatment strategies, and clinical outcome. UTI in critically ill and immunosuppressed patients admitted to ICU is a matter for concern in a healthcare setting due to the indication of invasive candidiasis (IC) and need for appropriate antifungal medications [30]. The mortality rate attributed to candidemia and invasive infections is approximately 30%. Concerns about fluconazole resistance primarily involve Nakaseomyces glabrata, Candida parapsilosis, and Candida auris, whereas Candida tropicalis infections exhibit less susceptibility [31]. In this study, we aimed to identify Candida spp. and risk factors, and to determine AFST patterns of isolates from the urine samples of COVID-19 hospitalized patients suffered from UTIs for the first time in Iran during the pandemic. The patients had encountered moderate to severe cases of COVID-19, necessitating hospitalization in the ICU and treatment with immunosuppressive drugs to manage the disease. The European Centre for Disease Prevention and Control (ECDC) recently reported Candida spp. as the seventh most frequently isolated microorganism causing UTI in Europe with a significant increase among critically ill patients [32].
Several studies have shown that the distribution of Candida spp. recovered from candiduria is changing worldwide [33,34,35], with an increasing frequency of drug-resistant NACs (e.g., C. glabrata, C. tropicalis, C. krusei). In our study, C. albicans was the most frequent Candida species isolated from UTI patients, followed by C. tropicalis, C. glabrata, C. krusei, and C. parapsilosis. Consistent with our findings, several studies indicated the superiority of C. albicans UTI over NCAs, with a rapid emergence of NACs [7,8,36,37] worldwide. In contrast, in a study by Santana in Brazil, C. tropicalis was found most commonly in UTI, whereas C. albicans was the second most common species [38], which might be explained by the different population and geographic area of study. In another recent report, from critically ill COVID-19 hospitalized patients in Brazil [29], candiduria was directly related to C. albicans, C. glabrata, and C. tropicalis. In our study, it was also evident that a longer hospitalization poses a significant predisposing factor with UTI. The prolonged exposure to the hospital environment may compromise the host’s immune defences, rendering them more susceptible to colonization and infection by Candida spp. [39]. This is corroborated by a previous study by Singulani and colleagues [29]. A similar study evaluated risk factors in hospitalized COVID-19 cases with candidiasis. C. albicans was the most prevalent species associated with candiduria symptoms [28].
The associated underlying diseases are similar to studies previously conducted in patients hospitalized for COVID-19 or other causes. For instance, in our study, as expected, many of the patients with indwelling urinary catheter usage showed UTIs, mirroring findings reported by Yazdanpanah [28], as catheterization and admission to the ICU is considered as an elevated risk of UTI. In our study, patients received empirical antibiotic treatment during hospitalization, and it impacted on Candida UTI. In studies on COVID-19 patients, 70–90% of patients received antimicrobial therapy, and only 10% had fungal or bacterial infections [40,41]. It has been investigated that long-term use of broad-spectrum antibiotics used in COVID-19 patients is a significant risk factor for fungal infection [42]. In addition, in our study, diabetes mellitus cases (a high-risk group caused by C. albicans and non-Candida albicans species [36,43,44,45]) accounted for the main group of COVID-19 patients (46.51%), further increasing the risk to UTI in our study.
Indeed, the global health burden of both diabetes and Candida spp. infections is on the rise, and COVID-19 and diabetes can have a compounding effect on the emerging of a fungal infection [46].
Although the general patterns of AFST against clinical isolates of Candida spp. have been studied, there is a lack of sufficient data associated with AFST of Candida isolates from COVID-19 patients with candiduria. According to our AFST findings, the majority of C. albicans isolates (70%) were sensitive to FLZ. FLZ is the treatment of choice for UTI due to high tissue and urine concentrations, and infrequent adverse effects [30]. None of the patients in this study received FLZ prophylaxis during the study, and no previous exposure to FLZ can account for the observed high rate of sensitivity among Candida spp. [47]. In the end, we can see a low rate of resistance to azole drugs among the Candida species recovered from UTI in our study. Additionally, two isolates of C. glabrata and one isolate of C. krusei were resistant to both FLZ and ITZ, which was also described before in some reports from Iran [28,48,49,50,51,52].
In our study, the most effective antifungals agents were FLZ and AMB, with low MIC values for C. albicans, a predominant isolate, in both drugs. From the perspective of availability, cost-effectiveness, and bioavailability, FLZ is a suitable drug as a first choice to define the most successful approach to the management of UTI [30]. Still, antifungal susceptibility testing is highly recommended for clinical isolates of Candida spp. because C. krusei has intrinsic resistance to FLZ [53], and C. glabrata species have been reported as having high MICs values or being FLZ resistant [47]. Despite there being no resistant Candida spp. to AMB in our study, the high cost and impracticality of AMB have led to its limited prescription in Iran for treating COVID-19 patients. As a limitation of this study, we were unable to test a variety of antifungal drugs against Candida spp. due to budget limitations in accessing those antifungals for this research. In addition, the number of patients was decreased due to the control of COVID-19 through vaccinations, which contributed to lowering the number of co-infections. In fact, while the sample size of this study is limited, it is reflective of the prevalence of the condition in our specific clinical setting (Emam Khomeini University hospital, Sari, Iran). Moreover, case series are often invaluable in highlighting patterns and generating hypotheses for larger studies. To fight this limitation, we ensured rigorous data collection and analysis to maximize the robustness of our findings despite the smaller cohort.
In summary, the growing knowledge of clinicians, and researchers regarding candiduria, its causative agent identification, and antifungal susceptibility pattern in high-risk patients with underlying disease, play a substantial role in the prophylaxis and effective treatments, as well as precise selection of antifungal drugs to mitigate drug resistance among Candida species, which has been rapidly growing these last years.

4. Materials and Methods

4.1. Patients and Clinical Specimen Processing

Urine samples were collected in a sterile container from COVID-19 patients with suspected UTI infection hospitalized in the ICU ward of Emam Khomeini University hospital, Sari, Iran, from January 2021 to September 2021. All patients had indwelling urinary catheters. This study was reviewed by ethical committee members of the Iran University of Medical sciences, and ethical approval was granted with number IR.IUMS.1400.586. The samples were transferred to microbiology laboratory immediately for microbiology assessment. Demographic data from patients (e.g., age, sex, the history of antifungal drugs and underlying disease) were recorded in the questionary form. COVID-19 was diagnosed based on positive real-time polymerase chain reaction (RT-PCR) tests for SARS-CoV-2, and candiduria was identified by Candida-positive urine cultures. This was a non-interventional study, and the authors did not have any influence on the prescription of antifungal treatment.

4.2. Identification of Isolates

4.2.1. Conventional Methods and Culture Condition

All urine samples were centrifuged, and the sediment used for microscopic evaluation to observe yeast and pseudohyphae. For the microscopic observation, the urine sediment was stained using lactophenol cotton blue to highlight cell structures and detect the differentiation of yeast and pseudohyphae. At first, Candida species were identified by the conventional method. For this, the sediments were cultured on sabouraud dextrose agar (SDA; Merck, Darmstadt, Germany) and incubated in 37c for 48 h. Candida species were presumptively identified by streaking to CHROMagar Candida (CHROMagar™, Sigma-Aldrich, St. Louis, MO, USA) based on the production of a specific colour [54]. Additionally, yeast colonies were cultured on cornmeal agar medium (Micromedia, Budapest, Hungary) supplemented with Tween® 80 (Sigma-Aldrich, USA) for the identification of Candida species based on their morphology.

4.2.2. Molecular Assay

Molecular identification was applied to confirm Candida species using 21-plex PCR and specific primers for each species [55]. For this purpose, DNA was extracted from Candida species (fresh colony from 24 h culture) using a Pouya gene DNA extraction Kit (Tehran, Iran). The quality and quantity of DNA was checked by a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and gel electrophoresis, respectively. DNA was amplified in a PCR reaction. Species-specific primers [55] were used for the precise identification of each Candida species. Species with failed identification in the first multiplex PCR were further tested by the second multiplex PCR, and in the case of obtaining negative results, isolates were checked by a third multiplex PCR [55]. PCR products were visualized on 2% agarose gel electrophoresis and checked visually by Gel Doc (Gel Doc XR+, Bio-Rad, Hercules, CA, USA). The identification of Candida species was performed by comparison of the sizes of the fragments with the references’ band profiles for each species.

4.3. Antifungal Susceptibility Testing

All isolates were tested for susceptibility against fluconazole (FLZ), amphotericin B (AMB), and itraconazole (ITZ) by the microdilution broth method, and according to the method of the Clinical and Laboratory Standards Institute (CLSI M27-A3/S4) guidelines [56]. Briefly, dilutions were prepared in RPMI-1640 medium (Roswell Park Memorial Institute; Sigma Chemical Co., St. Louis, MO, USA) in 96-well flat-bottom microtiter plates (NuncTM, Thermo Fisher Scientific, Illkirch-Graffenstaden, France). For ITZ, (ITZ; MIC range: 0.125–16 μg/mL; Sigma-Aldrich) and AMB, concentrations ranged from 0.016 to 16 g/mL, whereas for FLZ, it ranged from 0.063 to 64 g/mL. Each Candida isolate was inoculated at a concentration of 0.5–2.5 × 103 CFU/mL and incubated at 35 C for 24 h. Candida parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) were used for quality control. The growth of fungi in the wells was checked visually. MIC50 for FLZ and ITZ was considered as the minimum concentration of drugs inhibiting 50% of fungal growth, while for AMB, the MIC endpoint was the lowest concentration that inhibited 100% of fungal growth as compared with that of the drug-free control. MIC values of FLZ and ITZ were interpreted based on clinical breakpoints (CBP), whereas MIC for AMB was considered the epidemiological cut off, as a clinical breakpoint has not been reported for AMB in CLSI M27/S4 [56].

4.4. Statistical Analysis

Data analysis was conducted using SPSS version 24 (IBM Corp., New York, NY, USA). All AFST experiments were carried out in triplicate, and appropriate positive and negative controls were used for tests.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics13070633/s1, PCR product of Candida spp. recovered from urine culture of UTI patients and one figure of CHROMagar Candida used to the preliminary identification of Candida spp. based on the color production by each isolate.

Author Contributions

Conceptualization, M.R., S.F., Z.S.S. and S.R.M.; methodology, M.R., Z.S.S., L.V.L., S.M. and N.N.; validation: M.R. and C.F.R.; investigation: M.R. and L.V.L.; writing—original draft preparation, M.R. and J.B.; writing—review and editing, J.B., M.R. and C.F.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Iran University of Medical sciences, grant number IR.IUMS.1400.22127.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Iran University of Medical Sciences (protocol code IR.IUMS.FMD.REC.1400.586 and approved in 19 December 2021).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Lagunes, L.; Rello, J. Invasive candidiasis: From mycobiome to infection, therapy, and prevention. Eur. J. Clin. Microbiol. Infect. Dis. 2016, 35, 1221–1226. [Google Scholar] [CrossRef] [PubMed]
  2. Roudbary, M.; Kumar, S.; Kumar, A.; Černáková, L.; Nikoomanesh, F.; Rodrigues, C.F. Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID-19 patients. J. Fungi 2021, 7, 720. [Google Scholar] [CrossRef]
  3. Alhumaid, S.; Al Mutair, A.; Al Alawi, Z.; Alshawi, A.M.; Alomran, S.A.; Almuhanna, M.S.; Almuslim, A.A.; Bu Shafia, A.H.; Alotaibi, A.M.; Ahmed, G.Y.; et al. Coinfections with bacteria, fungi, and respiratory viruses in patients with SARS-CoV-2: A systematic review and meta-analysis. Pathogens 2021, 10, 809. [Google Scholar] [CrossRef]
  4. Lansbury, L.; Lim, B.; Baskaran, V.; Lim, W.S. Co-infections in people with COVID-19: A systematic review and meta-analysis. J. Infect. 2020, 81, 266–275. [Google Scholar] [CrossRef]
  5. Jain, N.; Kohli, R.; Cook, E.; Gialanella, P.; Chang, T.; Fries, B.C. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl. Environ. Microbiol. 2007, 73, 1697–1703. [Google Scholar] [CrossRef]
  6. Altinkaya Çavuş, M.; Sav, H. Opportunistic Candida Infections in Critical COVID-19 Patients. Pol. J. Microbiol. 2022, 71, 411–419. [Google Scholar] [CrossRef] [PubMed]
  7. Fisher, J.F.; Kavanagh, K.; Sobel, J.D.; Kauffman, C.A.; Newman, C.A. Candida urinary tract infection: Pathogenesis. Clin. Infect. Dis. 2011, 52 (Suppl. S6), S437–S451. [Google Scholar] [CrossRef] [PubMed]
  8. Sobel, J.D.; Fisher, J.F.; Kauffman, C.A.; Newman, C.A. Candida urinary tract infections—Epidemiology. Clin. Infect. Dis. 2011, 52 (Suppl. S6), S433–S436. [Google Scholar] [CrossRef] [PubMed]
  9. Revankar, S.G.; Hasan, M.S.; Revankar, V.S.; Sobel, J.D. Long-term follow-up of patients with candiduria. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30, 137–140. [Google Scholar] [CrossRef]
  10. Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2015, 62, e1–e50. [Google Scholar] [CrossRef]
  11. Pemán, J.; Ruiz-Gaitán, A. Candidemia from urinary tract source: The challenge of candiduria. Hosp. Pract. 2018, 46, 243–245. [Google Scholar] [CrossRef] [PubMed]
  12. Gajdács, M.; Dóczi, I.; Ábrók, M.; Lázár, A.; Burián, K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: Results from a 10-year retrospective survey. Cent. Eur. J. Urol. 2019, 72, 209–214. [Google Scholar]
  13. Biagi, M.J.; Wiederhold, N.P.; Gibas, C.; Wickes, B.L.; Lozano, V.; Bleasdale, S.C.; Danziger, L. Development of high-level echinocandin resistance in a patient with recurrent candida auris candidemia secondary to chronic candiduria. Open Forum Infect. Dis. 2019, 6, ofz262. [Google Scholar] [CrossRef] [PubMed]
  14. Osset-Trénor, P.; Pascual-Ahuir, A.; Proft, M. Fungal Drug Response and Antimicrobial Resistance. J. Fungi 2023, 9, 565. [Google Scholar] [CrossRef] [PubMed]
  15. Whaley, S.G.; Berkow, E.L.; Rybak, J.M.; Nishimoto, A.T.; Barker, K.S.; Rogers, P.D. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Species. Front. Microbiol. 2017, 7, 2173. [Google Scholar] [CrossRef] [PubMed]
  16. Pohl, C.H. Recent Advances and Opportunities in the Study of Candida albicans Polymicrobial Biofilms. Front. Cell. Infect. Microbiol. 2022, 12, 836379. [Google Scholar] [CrossRef] [PubMed]
  17. Malinovská, Z.; Čonková, E.; Váczi, P. Biofilm Formation in Medically Important Candida Species. J. Fungi 2023, 9, 955. [Google Scholar] [CrossRef]
  18. Nazari, T.; Sadeghi, F.; Izadi, A.; Sameni, S.; Mahmoudi, S. COVID-19-associated fungal infections in Iran: A systematic review. PLoS ONE 2022, 17, e0271333. [Google Scholar] [CrossRef] [PubMed]
  19. Arastehfar, A.; Carvalho, A.; van de Veerdonk, F.L.; Jenks, J.D.; Koehler, P.; Krause, R.; Cornely, O.A.; S Perlin, D.; Lass-Flörl, C.; Hoenigl, M. COVID-19 associated pulmonary aspergillosis (CAPA)—From immunology to treatment. J. Fungi 2020, 6, 91. [Google Scholar] [CrossRef]
  20. Dupont, D.; Menotti, J.; Turc, J.; Miossec, C.; Wallet, F.; Richard, J.C.; Argaud, L.; Paulus, S.; Wallon, M.; Ader, F.; et al. Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19). Med. Mycol. 2021, 59, 110–114. [Google Scholar] [CrossRef]
  21. Monte Junior, E.S.D.; Santos, M.E.L.D.; Ribeiro, I.B.; Luz, G.O.; Baba, E.R.; Hirsch, B.S.; Funari, M.P.; de Moura, E.G.H. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: A case report. Clin Endosc. 2020, 53, 746–749. [Google Scholar] [CrossRef] [PubMed]
  22. Mehta, S.; Pandey, A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus 2020, 12, e10726. [Google Scholar] [CrossRef] [PubMed]
  23. Arastehfar, A.; Shaban, T.; Zarrinfar, H.; Roudbary, M.; Ghazanfari, M.; Hedayati, M.-T.; Sedaghat, A.; Ilkit, M.; Najafzadeh, M.J.; Perlin, D.S. Candidemia among iranian patients with severe COVID-19 admitted to ICUs. J. Fungi 2021, 7, 280. [Google Scholar] [CrossRef] [PubMed]
  24. Posteraro, B.; Torelli, R.; Vella, A.; Leone, P.M.; De Angelis, G.; De Carolis, E.; Ventura, G.; Sanguinetti, M.; Fantoni, M. Pan-echinocandin-resistant candida glabrata bloodstream infection complicating COVID-19: A fatal case report. J. Fungi 2020, 6, 163. [Google Scholar] [CrossRef] [PubMed]
  25. García-Agudo, L.; Rodríguez-Iglesias, M.; Carranza-González, R. Nosocomial Candiduria in the Elderly: Microbiological Diagnosis. Mycopathologia 2018, 183, 591–596. [Google Scholar] [CrossRef] [PubMed]
  26. Nademi, A.; Shahrokh, H.; Kordbacheh, P.; Zaini, F.; Rezaie, S.; Mahmoudi, M.; Safara, M.; Moosa, H.; Fateh, R. Identification and antifungal susceptibility pattern of Candida species isolated from patients with nosocomial candiduria. J. Mycol. Res. 2015, 2, 77–84. [Google Scholar]
  27. Silva, L.N.; de Mello, T.P.; de Souza Ramos, L.; Branquinha, M.H.; Roudbary, M.; dos Santos, A.L.S. Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options. Curr. Top. Med. Chem. 2020, 20, 1951–1957. [Google Scholar] [CrossRef]
  28. Yazdanpanah, S.; Ahmadi, M.; Zare, Z.; Nikoupour, H.; Arabsheybani, S.; Jabrodini, A.; Eghtedarnejad, E.; Chamanpara, P.; Geramizadeh, B.; Anbardar, M.H.; et al. Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates. Mycopathologia 2023, 188, 9–20. [Google Scholar] [CrossRef]
  29. Singulani, J.L.; Silva, D.L.; Lima, C.M.; Magalhães, V.C.R.; Baltazar, L.M.; Moura, A.S.; Santos, A.R.O.; Fereguetti, T.; Martins, J.C.; Rabelo, L.F.; et al. COVID-19 and candiduria: An investigation of the risk factors and immunological aspects. Braz. J. Microbiol. 2023, 54, 1783–1793. [Google Scholar] [CrossRef]
  30. Hollenbach, E. To treat or not to treat—Critically ill patients with candiduria. Mycoses 2008, 51, 12–24. [Google Scholar] [CrossRef]
  31. Lass-Flörl, C.; Kanj, S.S.; Govender, N.P.; Thompson, G.R.; Ostrosky- Zeichner, L.; Govrins, M.A. Invasive candidiasis. Nat. Rev. Dis. Primers. 2024, 10, 20. [Google Scholar] [CrossRef] [PubMed]
  32. European Center for Disease Prevention and Control. HAI-Net PPSinteractive Database: Healthcare-Associated Infections and Antimi-Crobial Use in Acute Care Hospitals. Available online: https://www.ecdc.europa.eu/en/publications-data/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-5 (accessed on 25 May 2017).
  33. Gharaghani, M.; Taghipour, S.; Halvaeezadeh, M.; Mahmoudabadi, A.Z. Candiduria; A review article with specific data from Iran. Turk. J. Urol. 2018, 44, 445–452. [Google Scholar] [CrossRef]
  34. Aubron, C.; Suzuki, S.; Glassford, N.J.; Garcia-Alvarez, M.; Howden, B.P.; Bellomo, R. The epidemiology of bacteriuria and candiduria in critically ill patients. Epidemiol. Infect. 2015, 143, 653–662. [Google Scholar] [CrossRef] [PubMed]
  35. Voltan, A.R. Candiduria: Epidemiology, Resistance, Classical and Alternative Antifungals Drugs. SOJ Microbiol. Infect. Dis. 2014, 2, 1–7. [Google Scholar] [CrossRef]
  36. Gharanfoli, A.; Mahmoudi, E.; Torabizadeh, R.; Katiraii, F.; Faraji, S. Isolation, characterization, and molecular identification of Candida species from urinary tract infections. Curr. Med. Mycol. 2019, 5, 33–36. [Google Scholar] [CrossRef] [PubMed]
  37. Fazeli, A.; Kordbacheh, P.; Nazari, A.; Daie Ghazvini, R.; Mirhendi, H.; Safara, M.; Bakhshi, H.; Yaghoubi, R. Candiduria in Hospitalized Patients and Identification of Isolated Candida Species by Morphological and Molecular Methods in Ilam, Iran. Iran J. Public Health 2019, 48, 156–161. [Google Scholar] [PubMed]
  38. Santana, M.M.P.; Hoffmann-Santos, H.D.; Dias, L.B.; Tadano, T.; Karhawi, A.S.K.; Dutra, V.; Cândido, S.L.; Hahn, R.C. Epidemiological profile of patients hospitalized with candiduria in the Central-Western region of Brazil. Rev. Iberoam Micol. 2019, 36, 175–180. [Google Scholar] [CrossRef] [PubMed]
  39. Odabasi, Z.; Mert, A. Candida urinary tract infections in adults. World J. Urol. 2020, 38, 2699–2707. [Google Scholar] [CrossRef] [PubMed]
  40. Lai, C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 2020, 55, 105924. [Google Scholar] [CrossRef]
  41. Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020, 71, 2459–2468. [Google Scholar] [CrossRef]
  42. Coskun, A.S.; Durmaz, S.O. Fungal infections in COVID-19 intensive care patients. Pol. J. Microbiol. 2021, 70, 395–400. [Google Scholar] [CrossRef] [PubMed]
  43. Esmailzadeh, A.; Zarrinfar, H.; Fata, A.M.; Sen, T. High prevalence of candiduria due to non-albicans Candida species among diabetic patients: A matter of concern? J. Clin. Lab. Anal. 2018, 32, e22343. [Google Scholar] [CrossRef] [PubMed]
  44. Yismaw, G.; Asrat, D.; Woldeamanuel, Y.; Unakal, C. Prevalence of Candiduria in Diabetic Patients Attending Gondar University Hospital, Gondar, Ethiopia. Iran. J. Kidney Dis. 2013, 7, 102–107. Available online: https://www.ijkd.org/index.php/ijkd/article/view/834 (accessed on 12 January 2024). [PubMed]
  45. Talapko, J.; Meštrović, T.; Škrlec, I. Growing importance of urogenital candidiasis in individuals with diabetes: A narrative review. World J. Diabetes 2022, 13, 809–821. [Google Scholar] [CrossRef]
  46. Brothers, E.M.; Lidsky, K.; Simmons, J.; Nakagawa, T. A Child With COVID-19, Type 1 Diabetes, and Candida glabrata: A Case Report and Literature Review. Clin. Pediatr. 2021, 60, 554–558. [Google Scholar] [CrossRef] [PubMed]
  47. Bennett, J.E.; Izumikawa, K.; Marr, K.A. Mechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis. Antimicrob. Agents Chemother. 2004, 48, 1773–1777. [Google Scholar] [CrossRef] [PubMed]
  48. Badiee, P.; Badali, H.; Boekhout, T.; Diba, K.; Moghadam, A.G.; Nasab, A.H.; Jafarian, H.; Mohammadi, R.; Mirhendi, H.; Najafzadeh, M.J.; et al. Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: Comparison of colonizing and infecting isolates. BMC Infect. Dis. 2017, 17, 727. [Google Scholar] [CrossRef]
  49. Arastehfar, A.; Daneshnia, F.; Zomorodian, K.; Najafzadeh, M.J.; Khodavaisy, S.; Zarrinfar, H.; Hagen, F.; Shahrabadi, Z.Z.; Lackner, M.; Mirhendi, H.; et al. Low level of antifungal resistance in iranian isolates of candida glabrata recovered from blood samples in a multicenter study from 2015 to 2018 and potential prognostic values of genotyping and sequencing of PDR1. Antimicrob. Agents Chemother. 2019, 63, e02503-18. [Google Scholar] [CrossRef] [PubMed]
  50. Erami, M.; Raiesi, O.; Momen-Heravi, M.; Getso, M.I.; Fakhrehi, M.; Mehri, N.; Yarahmadi, M.; Amiri, S.; Raissi, V.; Hashemi, S.J. Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia. Microb. Pathog. 2022, 166, 105520. [Google Scholar] [CrossRef]
  51. Arastehfar, A.; Yazdanpanah, S.; Bakhtiari, M.; Fang, W.; Pan, W.; Mahmoudi, S.; Pakshir, K.; Daneshnia, F.; Boekhout, T.; Ilkit, M.; et al. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018). Med. Mycol. 2021, 59, 422–430. [Google Scholar] [CrossRef]
  52. Arastehfar, A.; Khanjari, S.; Zareshahrabadi, Z.; Fang, W.; Pan, W.; Asadpour, E.; Daneshnia, F.; Ilkit, M.; Boekhout, T.; Perlin, D.S.; et al. Clinical and microbiological features of candiduria in critically ill adult patients in Shiraz, Iran (2016–2018): Deviations from international guidelines and fluconazole therapeutic failure. Med. Mycol. 2021, 59, 600–607. [Google Scholar] [CrossRef] [PubMed]
  53. Jamiu, A.T.; Albertyn, J.; Sebolai, O.M.; Pohl, C.H. Update on Candida krusei, a potential multidrug-resistant pathogen. Med. Mycol. 2021, 59, 14–30. [Google Scholar] [CrossRef]
  54. Pfaller, M.A.; Houston, A.; Coffmann, S. Application of CHROMagar Candida for Rapid Screening of Clinical Specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 1996, 34, 58–61. [Google Scholar] [CrossRef] [PubMed]
  55. Arastehfar, A.; Fang, W.; Pan, W.; Lackner, M.; Liao, W.; Badiee, P.; Zomorodian, K.; Badali, H.; Hagen, F.; Lass-Flörl, C.; et al. YEAST PANEL multiplex PCR for identification of clinically important yeast species: Stepwise diagnostic strategy, useful for developing countries. Diagn. Microbiol. Infect. Dis. 2018, 93, 112–119. [Google Scholar] [CrossRef] [PubMed]
  56. Pfaller, M.A.; Diekema, D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 2012, 50, 2846–2856. [Google Scholar] [PubMed]
Table 1. Patients’ demographic data collected from medical records.
Table 1. Patients’ demographic data collected from medical records.
Variablen (%)
GenderMale10 (25.64%)
Female29 (74.35%)
Age
(20–70 years)		<302 (5.12%)
30–6017 (43.58%)
>6020 (51.28%)
Predisposing factorsDiabetes (type 2)18 (46.51%)
Immunosuppressive drugs12 (30.76%)
Cancer4 (10.25%)
Antibiotics therapy (2 weeks)15 (38.5%)
Length of hospitalization (6–12 days)25 (64%)
Table 2. Antifungal susceptibility testing of three antifungal drugs against Candida isolates according to (CLSIM27/S4) guidelines.
Table 2. Antifungal susceptibility testing of three antifungal drugs against Candida isolates according to (CLSIM27/S4) guidelines.
Candida spp.FLZ (μg/mL)ITZ (μg/mL)AMB (μg/mL)
C. albicans (n = 20)S
≤2		R
≥8		SDD
4–8		S
≤0.125		R
≥1		SDD
0.25–0.5		S
≤2		R
>2		SDD
--
14 (70%)1 (5%)5 (15%)5 (15%)--15 (75%)20 (100%)----
C. tropicalis (n = 15)7 (47%)3 (20%)5 (33%)2 (13%)3 (20%)10 (66%)15 (100%)----
C. glabrata (n = 2)SR
≥64		SDD
≤32		S
≤0.125		R
≥2		SDD
0.25–0.5 		S
≤1		R
≥2		--
--2 (100%)----1 (50%)1 (50%)2 (10%)----
C. parapsilosis
(n = 1)		----1 (100%)1 (10%)----1 (10%)----
C. krusei
(n = 1)		--1 (100%)----1 (10%)----1 (100%)--
Note: S—sensitive; R—Resistance; SDD—susceptible dose dependent.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Shiyadeh, Z.S.; Farahyar, S.; Vahedi Larijani, L.; Beardsley, J.; Nouri, N.; Mahmoudi, S.; Roudbar Mohammadi, S.; Rodrigues, C.F.; Roudbary, M. Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran: Candida Species Distribution and Antifungal Susceptibility Patterns. Antibiotics 2024, 13, 633. https://doi.org/10.3390/antibiotics13070633

AMA Style

Shiyadeh ZS, Farahyar S, Vahedi Larijani L, Beardsley J, Nouri N, Mahmoudi S, Roudbar Mohammadi S, Rodrigues CF, Roudbary M. Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran: Candida Species Distribution and Antifungal Susceptibility Patterns. Antibiotics. 2024; 13(7):633. https://doi.org/10.3390/antibiotics13070633

Chicago/Turabian Style

Shiyadeh, Zeinab Soleimani, Shirin Farahyar, Laleh Vahedi Larijani, Justin Beardsley, Noura Nouri, Shahram Mahmoudi, Shahla Roudbar Mohammadi, Célia Fortuna Rodrigues, and Maryam Roudbary. 2024. "Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran: Candida Species Distribution and Antifungal Susceptibility Patterns" Antibiotics 13, no. 7: 633. https://doi.org/10.3390/antibiotics13070633

APA Style

Shiyadeh, Z. S., Farahyar, S., Vahedi Larijani, L., Beardsley, J., Nouri, N., Mahmoudi, S., Roudbar Mohammadi, S., Rodrigues, C. F., & Roudbary, M. (2024). Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran: Candida Species Distribution and Antifungal Susceptibility Patterns. Antibiotics, 13(7), 633. https://doi.org/10.3390/antibiotics13070633

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop